Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05BPC
|
||||
| Former ID |
DIB006927
|
||||
| Drug Name |
Tiprelestat
|
||||
| Synonyms |
Elafin; Recombinant leukocyte elastase/proteinase-3 inhibitor (iv, inflammation), Proteo Biotech
|
||||
| Indication | Myocardial infarction [ICD9: 410; ICD10:I21, I22] | Phase 2 | [1] | ||
| Company |
Proteo Biotech AG
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C254H416N72O75S10
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Leukocyte proteinase-3 | Target Info | Modulator | ||
| Leukocyte elastase | Target Info | Modulator | |||
| KEGG Pathway | Transcriptional misregulation in cancer | ||||
| Systemic lupus erythematosus | |||||
| Pathway Interaction Database | C-MYB transcription factor networkupa_upar_pathway:Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| C-MYB transcription factor network | |||||
| Reactome | Common Pathway of Fibrin Clot FormationR-HSA-1442490:Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | ||||
| Human Complement System | |||||
| Degradation of collagen | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021706) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.